Explore health news coverage from National Health Underwriters: Sector news category — verified health events only (FDA, guidelines, major studies).
Sector news category — verified health events only (FDA, guidelines, major studies)
The August 5, 2026 approval of oveporexton brings the first orexin receptor agonist to market — wakefulness restored, not stimulated. What patients should ask.
Written by Grace Mensah
The July 15, 2026 approval of enlicitide turns an injection class costing thousands per year into a daily pill. Trial numbers, coverage questions, what's next.
Written by Grace Mensah
The June 17, 2026 approval of tebipenem lets some kidney-infection patients leave the infusion chair for a pill — if stewardship rules hold the line on use.
Written by Grace Mensah
The May 22, 2026 approval of bulevirtide brings the entry-blocker used in Europe since 2020 to US adults with chronic hepatitis delta. Who should be tested.
Written by Grace Mensah
The May 1, 2026 approval of epdegestrant targets ESR1-mutated HR-positive metastatic breast cancer. Why genomic testing at relapse decides who qualifies.
Written by Grace Mensah
The April 1, 2026 approval of orforglipron brings GLP-1 weight-loss therapy to a daily tablet manufactured at standard scale. Efficacy, side effects, coverage.
Written by Grace Mensah
The March 17, 2026 approval of icotrokinra blocks the IL-23 pathway orally. What patients should weigh on efficacy, monitoring, and coverage.
Written by Grace Mensah
The February 20, 2026 approval of milsaperidone adds a fresh side-effect profile to a class dominated by generics. What it means for patients and payers.
Written by Grace Mensah
A January 5, 2026 announcement tied to a presidential memorandum set off schedule changes, court challenges, and a postponed ACIP meeting. What parents should know.
Written by Grace Mensah
The January 12, 2026 approval of copper histidinate gives infants with the rare ATP7A disorder a standardized, FDA-reviewed treatment option.
Written by Grace Mensah